publication date: Jun 7, 2012
|
author/source: Alto Marketing Limited
CRO
adds TRAC to service portfolio for pre-clinical ADME-Tox studies Plexpress, developer of the innovative
TRAC platform for high-throughput gene expression analysis, has announced it
will partner with SBW to provide SBW's customers with access to Plexpress'
novel technology. SBW, a contract research organisation serving the drug
discovery market, will offer Plexpress' pre-validated TRAC Cytochrome P450
(CYP) family multiplex assays as part of its portfolio for investigating
in
vitro drug interactions and pre-clinical ADME-Tox profiles. Such a service
is expected to be very popular, especially given a recent
draft report from the FDA, which suggests that drug discovery researchers
use CYP mRNA induction, rather than CYP activity, to assess drug metabolism and
activity
(1).
TRAC (Transcript Analysis with the
aid of Affinity Capture) technology is a new approach to measuring gene
expression changes that offers several benefits over qPCR and microarrays,
including higher sample throughput and increased assay speed, while
simultaneously reducing technical variation.
For more information about how
TRAC could boost the efficiency of your drug discovery pipeline, please visit
www.plexpress.com.
For more information
about the new SBW service utilising TRAC, view
the
full release by visiting the SBW website or contact SBW directly at
info@sbw.fi.
Reference:
1. FDA Guidance for Industry Report (Feb
2012):
Drug
Interaction Studies Study Design, Data Analysis, Implications for Dosing, and
Labeling Recommendations
About Plexpress
Plexpress was established as a spinoff from the Finnish
Technology Research Center VTT in 2007. Including R&D at VTT, the company's
TRAC technology has been developed continuously for nearly 10 years and it has
been documented in over 15 publications. The technology was originally
developed for demanding bioprocess applications, which required a very robust
solution for gene expression analysis. Since starting operations in 2008, the
company has carried out over 50 projects using the TRAC technology in the
fields of pharmaceutical development and academic research.
About SBW
SBW is an integrated contract
research organization (CRO), located in Helsinki, Finland and has offices also
in Germany and North-America. We operate under the brands SBW/Biodix, SBW/Toxis
and SBW/novamass. We offer comprehensive services and platforms for drug
discovery, functional food ingredients testing, REACH chemical safety
assessment and related life science areas. Our services have more than 100
customers in aroung 20 countries in Europe, Asia and US. We offer services on a
fee for service -basis as well as contracting early discovery projects on
milestone reward basis. As a proof of our model, we bring our expertise and
experience from more than 600 engagements with customers ranging from virtual
Biotechs to several top 10 Pharmaceutical companies. We also promote industry?academia partnerships and are involved in many academic
research projects aiming to provide novel innovation services. We are also
authors in over 60 peer-reviewed research papers on drug research and
technologies since 2005.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.